Cleared Traditional

SimpleSense-BP, SimpleSense-BP Software Application (K232053) - FDA 510(k) Clearance

Class II Cardiovascular device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K232053 · Nanowear, Inc. · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 2023
Decision
150d
Days
Class 2
Risk

K232053 is an FDA 510(k) clearance for the SimpleSense-BP, SimpleSense-BP Software Application. Classified as System, Measurement, Blood-pressure, Non-invasive (product code DXN), Class II - Special Controls.

Submitted by Nanowear, Inc. (Brooklyn, US). The FDA issued a Cleared decision on December 8, 2023 after a review of 150 days - an extended review cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1130 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.

View all Nanowear, Inc. devices

Submission Details

510(k) Number K232053 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 11, 2023
Decision Date December 08, 2023
Days to Decision 150 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
25d slower than avg
Panel avg: 125d · This submission: 150d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DXN System, Measurement, Blood-pressure, Non-invasive
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1130
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DXN System, Measurement, Blood-pressure, Non-invasive

All 279
Devices cleared under the same product code (DXN) and FDA review panel - the closest regulatory comparables to K232053.
Blood Pressure Monitor
K233130 · Guangdong Transtek Medical Electronics Co., Ltd. · Dec 2023
Digital Blood Pressure Monitor (Model: YB-800)
K231478 · Wenzhou Yosun Medical Technology Co.,Ltd · Dec 2023
Wrist Blood Pressure Monitor
K232815 · Zhuhai Yueja Medical Device Technology Co., Ltd. · Dec 2023
Electronic Blood Pressure Monitor, model: HTD6602US
K223170 · Hetaida Technology Co., Ltd. · Dec 2023
Electronic Blood Pressure Monitor
K232814 · Zhuhai Yueja Medical Device Technology Co., Ltd. · Dec 2023
Digital Blood Pressure Monitor
K231250 · Guangdong Genial Technology Co., Ltd. · Nov 2023